LIMINATUS PHARMA, INC. Operating Expenses
LIMINATUS PHARMA, INC. (LIMN) reported Operating Expenses of $1.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- LIMINATUS PHARMA, INC. operating expenses for the quarter ending 2026-06-30 was $1.38M, a 23.31% increase year-over-year.
- LIMINATUS PHARMA, INC. operating expenses for the quarter ending 2026-03-31 was $1.10M, a 316.66% increase year-over-year.
- LIMINATUS PHARMA, INC. operating expenses for the quarter ending 2025-12-31 was $884.21K, a 429.22% increase year-over-year.
- LIMINATUS PHARMA, INC. operating expenses for the quarter ending 2025-09-30 was $701.17K, a 29.09% increase year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.38M 10-Q · filed 2026-08-14 | $2.48M 10-Q · filed 2026-08-14 | $3.36M derived: sum of 3 quarters · filed 2026-08-14 | $4.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.10M S-1 · filed 2026-06-24 | $1.99M derived: sum of 2 quarters · filed 2026-06-24 | $2.69M derived: sum of 3 quarters · filed 2026-06-24 | $3.80M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $884.21K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $1.59M derived: sum of 2 quarters · filed 2026-06-24 | $2.70M derived: sum of 3 quarters · filed 2026-08-14 | $2.97M S-1 · filed 2026-06-24 |
| 2025-09-30 | $701.17K 10-Q · filed 2025-11-14 | $1.82M derived: sum of 2 quarters · filed 2026-08-14 | $2.08M 10-Q · filed 2025-11-14 | $2.25M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-14 | $1.38M 10-Q · filed 2026-08-14 | $1.55M derived: sum of 3 quarters · filed 2026-08-14 | $2.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $264.22K S-1 · filed 2026-06-24 | $431.30K derived: sum of 2 quarters · filed 2026-06-24 | $974.44K derived: sum of 3 quarters · filed 2026-06-24 | $1.88M derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | $167.08K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $710.22K derived: sum of 2 quarters · filed 2026-06-24 | $1.62M derived: sum of 3 quarters · filed 2026-06-24 | $3.33M S-1 · filed 2026-06-24 |
| 2024-09-30 | $543.15K 10-Q · filed 2025-11-14 | $1.45M derived: sum of 2 quarters · filed 2025-11-14 | $3.16M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $909.22K 10-Q · filed 2025-10-06 | $2.62M 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |